Search
Maxy-G34
go.drugbank.com/drugs/DB05718InvestigationalMAXY-G34 is a pegylated variant of human granulocyte-colony stimulating factor (G-CSF). This variant contains multiple non-naturally occurring lysines that have been introduced into alpha helixes of wild type human G-CSF as PEGylation si...
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigationalElafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist that works to inhibit bile acid synthesis. On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary b...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersRomidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAleglitazar
go.drugbank.com/drugs/DB08915InvestigationalAleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes.
Efinaconazole
go.drugbank.com/drugs/DB09040ApprovedInvestigationalEfinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North ...
Dexchlorpheniramine
go.drugbank.com/drugs/DB13679InvestigationalIt is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsBertilimumab
go.drugbank.com/drugs/DB05429InvestigationalBertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. It is developed by MedImmune for the treatment of Allergic Rhinitis.
Omapatrilat
go.drugbank.com/drugs/DB00886ExperimentalThis drug from BMS was not approved by the FDA due to angioedema safety concerns. … Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE).
LS11
go.drugbank.com/drugs/DB05918InvestigationalLS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. … After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death.